Compare BDC & BLCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BDC | BLCO |
|---|---|---|
| Founded | 1902 | 1853 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Ophthalmic Goods |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.6B | 5.9B |
| IPO Year | 1994 | 2022 |
| Metric | BDC | BLCO |
|---|---|---|
| Price | $113.76 | $16.32 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 11 |
| Target Price | ★ $162.50 | $18.45 |
| AVG Volume (30 Days) | 351.2K | ★ 378.4K |
| Earning Date | 04-30-2026 | 04-29-2026 |
| Dividend Yield | ★ 0.16% | N/A |
| EPS Growth | ★ 23.13 | N/A |
| EPS | ★ 1.30 | N/A |
| Revenue | $2,715,194,000.00 | ★ $5,101,000,000.00 |
| Revenue This Year | $8.91 | $8.65 |
| Revenue Next Year | $4.70 | $5.59 |
| P/E Ratio | $86.95 | ★ N/A |
| Revenue Growth | ★ 10.33 | 6.47 |
| 52 Week Low | $102.49 | $10.83 |
| 52 Week High | $159.99 | $18.92 |
| Indicator | BDC | BLCO |
|---|---|---|
| Relative Strength Index (RSI) | 32.72 | 51.18 |
| Support Level | $111.12 | $16.26 |
| Resistance Level | $123.62 | $17.11 |
| Average True Range (ATR) | 4.97 | 0.47 |
| MACD | -1.81 | -0.02 |
| Stochastic Oscillator | 7.53 | 56.18 |
Belden Inc is a supplier of complete connection solutions. It has two segments, Smart Infrastructure Solutions and Automation Solutions. Smart Infrastructure Solutions provides network infrastructure and broadband solutions, serving markets such as data centers, government, healthcare, and broadband and wireless service providers, with products including copper and fiber cable and connectivity solutions. Automation Solutions provides digitization and automation solutions that enable IT OT convergence and support acquisition, transmission, orchestration, and management, serving markets including Warehousing and Logistics, Energy, Transportation, and Discrete Manufacturing. The company operates in the Americas, EMEA, and APAC, with maximum revenue coming from the Americas.
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.